ClinicalTrials.gg
CompletedNCT02271438Updated Jun 6, 2016

A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

A Phase 1 interventional study of Ibrutinib and Moxifloxacin in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of ibrutinib, to compare the pharmacokinetics of ibrutinib after single oral administration of 840 mg and 1680 mg and to assess the effects of a single dose of ibrutinib on QT/QTc intervals and electrocardiogram (ECG) in healthy adults.

Read the detailed description

The study consists of 2 parts: Part 1 and Part 2. Part 1 is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving), single-center, 2-period, sequential design part. It consists of a Screening phase (Day-21 to -2), Treatment Period 1 and Treatment Period 2. In treatment period 1, 8 participants including two women will receive 840 milligram (mg) ibrutinib capsules + 6 placebo capsules. In treatment period 2, participants will receive 1680 mg ibrutinib capsules. Treatment periods will be separated by a Washout period of not less than 7 days. A high-fat breakfast will be provided 2 hours before dosing. Blood samples will be collected after each dosing for pharmacokinetic assessments.

Part 2 is a randomized (the study medication is assigned by chance), placebo (an inactive substance that is compared with a medication to test whether the medication has a real effect in a clinical study) and positive-controlled (participants are assigned to either a recognized effective treatment or the study medication), double-blind (neither physician nor participant knows the treatment that the participant receives), single dose, and 4-way crossover (the same medications are provided to all participants but in a different sequence) part. Participants will receive either of the 4 treatments: Treatment A (Ibrutinib 1680 mg + moxifloxacin-matching placebo); Treatment B (Ibrutinib 840 mg+ ibrutinib-matching placebo + moxifloxacin-matching placebo); Treatment C (ibrutinib-matching placebo + moxifloxacin-matching placebo); and Treatment D: (moxifloxacin 400 mg + ibrutinib-matching placebo). Each treatment period will be separated by a Washout period of not less than 7 days. Electrocardiogram (ECG) will be recorded. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Ibrutinib
  • Moxifloxacin
  • Cardiac Repolarization
  • Electrocardiogram
  • QTc interval
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must sign an document indicating they understand the purpose of the study and procedures
  • Must have a (BMI) of between 18 and 30 kg/m\^2, inclusive
  • Must have a body weight of not less than 50 kg
  • Must have a blood pressure between 90 and 140 mmHg inclusive, systolic, and no higher than 90 mmHg diastolic at screening
  • Must have an average of triplicate 12-lead recordings, completed within 5 minutes total, consistent with normal cardiac conduction and function

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness
  • Clinically significant abnormal physical examination, vital signs or 12 lead
  • History of clinically relevant heart rhythm disturbances including atrial, junctional, re-entry, and ventricular tachycardias, and heart blocks
  • Use of any prescription or nonprescription medication (including vitamins and herbal supplements
  • Donated blood or blood products or had substantial loss of blood within 3 months before screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Part 1: Ibrutinib 840 milligram (mg)

    Participants will receive ibrutinib 840 mg (6\*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.

    Drug: Ibrutinib

  • Experimental
    Part 1: Ibrutinib 1680 mg

    Participants will receive ibrutinib 1680 mg (12\*140 mg capsules) on Day 1 of Part 1, Period 2.

    Drug: Ibrutinib

  • Experimental
    Part 2: Treatment A

    Participants will receive ibrutinib, 1680 mg (12\*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.

    Drug: Ibrutinib · Drug: Moxifloxacin-matching placebo

  • Experimental
    Part 2: Treatment B

    Participants will receive ibrutinib, 840 mg (6\*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.

    Drug: Ibrutinib · Drug: Moxifloxacin-matching placebo

  • Experimental
    Part 2: Treatment C

    Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.

    Drug: Ibrutinib-matching placebo · Drug: Moxifloxacin-matching placebo

  • Experimental
    Part 2: Treatment D

    Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.

    Drug: Moxifloxacin · Drug: Ibrutinib-matching placebo

Interventions

  • Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

  • Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.

  • DrugIbrutinib-matching placebo

    Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.

  • DrugMoxifloxacin-matching placebo

    Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.

06

What researchers measure

Primary outcomes

  1. Change from baseline in QTc interval

    The QTc interval, as measured by electrocardiograms will evaluate the potential effect of ibrutinib on QTc interval duration.

    Time frame: Baseline (predose) up to Day 4

  2. Number of Participants with Adverse events

    Time frame: Up to Day 12 of the follow-up period

Secondary outcomes

  1. Change from baseline in RR interval

    The RR interval is the portion between two consecutive R waves in the electrocardiogram.

    Time frame: Baseline (predose) up to Day 4

  2. Change from baseline in heart rate

    Time frame: Baseline (predose) up to Day 4

  3. Change from baseline in PR interval

    The PR interval is the portion of the electrocardiogram between the onset of the P wave (atrial depolarization) and the QRS complex (ventricular depolarization).

    Time frame: Baseline (predose) up to Day 4

  4. Change from baseline in QRS interval

    The QRS interval is the interval from the beginning of the Q wave to the termination of the S wave, representing the time for ventricular depolarization.

    Time frame: Baseline (predose) up to Day 4

  5. Plasma concentration of ibrutinib following administration of a single dose

    Plasma concentrations of ibrutinib are used to evaluate when the highest concentration is achieved in the body and how long it stays in the body.

    Time frame: Predose (before tablet intake), up to 72 hours after dose

  6. Plasma concentration of the Metabolite, PCI-45227, following administration of a single dose of ibrutinib

    Plasma concentrations of the metabolite, PCI-45227, are used to evaluate when the highest concentration is achieved in the body and how long it stays in the body.

    Time frame: Predose (before tablet intake), up to 72 hours after dose

  7. Plasma concentration of moxifloxacin following administration of a single dose

    Plasma concentrations of moxifloxacin are used to evaluate when the highest concentration is achieved in the body and how long it stays in the body.

    Time frame: Predose (before tablet intake), up to 72 hours after dose

07

Study locations

1 site
  • Merksem, Belgium
08

References and documents

Publications

  • de Jong J, Hellemans P, Jiao JJ, Huang Y, Mesens S, Sukbuntherng J, Ouellet D. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemother Pharmacol. 2017 Dec;80(6):1227-1237. doi: 10.1007/s00280-017-3471-x. Epub 2017 Oct 28. Erratum In: Cancer Chemother Pharmacol. 2018 Feb;81(2):423. doi: 10.1007/s00280-017-3490-7. PubMed 29080970 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Apr 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2014
First posted
Oct 22, 2014
Start
Oct 2014
Primary completionActual
Apr 2015
CompletionActual
May 2015
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02271438
Responsible party
Sponsor
First posted
Oct 22, 2014
Start date
Oct 2014
Primary completion
Apr 2015
Completion
May 2015
Last update
Jun 6, 2016

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Moxifloxacin

Start the discussion